<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hormone regimens for adult transgender persons</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hormone regimens for adult transgender persons</h1>
<div class="graphic"><div class="figure"><div class="ttl">Hormone regimens for adult transgender persons</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Dose range</td> <td class="subtitle1">Comment</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Transfeminine regimens<sup>*</sup></td> </tr> <tr> <td class="subtitle3_left" colspan="3"><strong>Estrogens</strong><sup>¶ </sup></td> </tr> <tr> <td class="indent2">Oral: estradiol (17-beta-estradiol valerate)</td> <td>2 to 6 mg/day</td> <td>Although some providers give higher doses of oral estradiol (greater than 6 mg/day), we suggest that only doses less than or equal to 6 mg/day be used.</td> </tr> <tr> <td class="indent2">Transdermal: estradiol patch</td> <td>0.025 to 0.2 mg per 24 hours, changed once or twice weekly, depending on specific preparation type</td> <td>Lower risk of thromboembolism compared with oral estrogen preparations.</td> </tr> <tr> <td class="indent2">Transdermal: estradiol gel</td> <td>0.25 to 1.25 mg applied once a day</td> <td>Lower risk of thromboembolism compared with oral estrogen preparations.</td> </tr> <tr> <td class="indent2" colspan="3">Parenteral</td> </tr> <tr> <td class="indent3">Estradiol valerate</td> <td>5 to 20 mg IM every two weeks</td> <td rowspan="2">Prolonged time to onset of effect and steady state, greater risk of accumulation and overdose.</td> </tr> <tr> <td class="indent3">Estradiol cypionate</td> <td>2 to 10 mg IM every week</td> </tr> <tr> <td class="subtitle3_left" colspan="3"><strong>Antiandrogens<sup>*</sup></strong></td> </tr> <tr> <td class="indent2">Spironolactone</td> <td>100 to 300 mg/day oral</td> <td>Monitor blood pressure and electrolytes.</td> </tr> <tr> <td class="indent2">Cyproterone acetate</td> <td>10 mg/day oral</td> <td>10 mg daily for a maximal duration of 2 years is recommended.</td> </tr> <tr> <td class="subtitle3_left" colspan="3"><strong>GnRH agonists</strong></td> </tr> <tr> <td class="indent2">Leuprolide</td> <td> <p>3.75 to 7.5 mg IM depot monthly</p> <p><strong>or</strong></p> 11.25 mg IM depot every 3 months</td> <td>Inhibits gonadotropin secretion.</td> </tr> <tr> <td class="indent2">Goserelin</td> <td>3.6 mg SQ implant monthly</td> <td>Expensive.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Transmasculine regimens</td> </tr> <tr> <td class="subtitle3_left" colspan="3"><strong>Testosterone</strong><sup>Δ</sup></td> </tr> <tr> <td class="indent2" colspan="3">Parenteral</td> </tr> <tr> <td class="indent3">Testosterone enanthate or cypionate</td> <td> <p>50 to 100 mg IM or SQ every week</p> <p><strong>or</strong></p> 100 to 200 mg IM every two weeks</td> <td>Weekly injections produce less peak-trough variation in effect (eg, mood); injection site reaction may occur.</td> </tr> <tr> <td class="indent3">Testosterone undecanoate<sup>◊</sup></td> <td>1000 mg IM every 10 to 12 weeks</td> <td>Produces stable physiologic testosterone levels over 10 to 13 weeks.</td> </tr> <tr> <td class="indent2" colspan="3">Transdermal</td> </tr> <tr> <td class="indent3">Testosterone gel 1% and 1.6%</td> <td>5 to 10 grams of gel per day (equivalent to 50 to 100 mg/day testosterone)</td> <td>Less variation in serum testosterone levels than injectable preparations; gel formulations can result in interpersonal transfer if contact occurs before fully dried (rare).</td> </tr> <tr> <td class="indent3">Testosterone patch</td> <td>2.5 to 7.5 mg/day transdermal</td> <td>Transdermal patch may produce lower serum testosterone levels and more skin irritation compared with gels.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Suggestions shown in table are based upon case descriptions and experience. Regimen and dose must be carefully individualized based upon patient age, goals of therapy, whether pre- or postgonadectomy, and comorbid medical conditions and risks. Refer to UpToDate topics on transgender men and transgender females.</div><div class="graphic_footnotes"><p>GnRH: gonadotropin-releasing hormone; 
        IM: intramuscular; 
        SQ: subcutaneous.</p>
<p>* Dose of estrogen should be adjusted according to serum 17-beta-estradiol levels (ie, 100 to 200 pg/mL) and effect. Lower doses of estradiol are generally sufficient for feminization goals when combined with an antiandrogen, GnRH agonist, or after gonadectomy. Antiandrogen therapy is discontinued after gonadectomy.</p>
<p>¶  Synthetic estrogens (eg, ethinyl estradiol) are not recommended, due to elevated risk of thromboembolic disease, cardiovascular mortality, and inability to regulate dose by measurement of serum levels.</p>
<p>Δ Doses of testosterone should be adjusted according to serum testosterone levels (ie, normal male range 320 to 1000 ng/dL) and effect. Time to onset of effect of parenteral preparations may be less than with transdermal preparations. Supplemental agents such as depot medroxyprogesterone 150 mg every 3 months or oral medroxyprogesterone 5 to 10 mg/day or oral lynestrenol 5 to 10 mg/day (not available in the United States) have been used as an add-on option when starting testosterone therapy to induce cessation of menses.</p>
    
    ◊ 1000 mg initially, followed by an injection at 6 weeks, then at 12-week intervals.</div><div class="graphic_reference">Adapted from: Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017; 102:3869.</div><div id="graphicVersion">Graphic 69460 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
